Bo Lu, MD
111 S. 11th Street
Philadelphia, PA 19107
(215) 503-0013 fax
Most Recent Peer-reviewed Publications
- Modeling the overall survival of patients with advanced-stage non-small cell lung cancer using data of routine laboratory tests
- A novel radiation-induced p53 mutation is not implicated in radiation resistance via a dominant-negative effect
- Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer
- Prevention of gross setup errors in radiotherapy with an efficient automatic patient safety system
- Prevention of gross setup errors in radiotherapy with an efficient automatic patient safety system.
Shanghai Medical University, Peoples Republic of China - 1987
University of California School of Medicine
University of Rochester Medicine & Dentistry, NY
Thomas Jefferson University Hospital
Methodist Hospital Division of Thomas Jefferson University Hospital
Research and Clinical Interests
I am a board-certified Radiation Oncologist who comes to Jefferson from Vanderbilt University in Nashville, Tenn., where I served as an Ingram associate professor with tenure in the Department of Radiation Oncology and Cancer Biology of the University’s School of Medicine. I was also an attending radiation oncologist at the Vanderbilt University Medical Center, member of the Ingram Cancer Center, and director of the Translational Research Program and Lung Cancer Research Program.
I received a Ph.D. in Cell and Molecular Biology from Baylor School of Medicine in Houston and a Doctorate in Medicine from Shanghai Medical University in China. I completed my residency in radiation oncology at the University of Southern California, School of Medicine.
I focus on radiation-induced cell death in lung patients, among other basic science areas. My clinical interests include the integration of novel targeted agents in the treatment of lung cancer, radiosurgery for lung cancer, and reduction of toxicities from thoracic radiation. More recently, I have looked at cancer stem cells for enhancing radiotherapy in a setting of lung cancer.